Beta cell replacement therapy by Gołębiewska, Justyna et al.
 REVIEW ARTICLE ISSN 2450–7458
344
Justyna Gołębiewska1 , Bogumił Wolnik2 , Michał Hoffmann2, Piotr Witkowski3,  
Tomasz Stefaniak4, Alicja Dębska-Ślizień1
1Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk 
2Department of Hypertension and Diabetology, Medical University of Gdańsk 
3Transplantation Institute, University of Chicago 
4Department of General, Endocrine and Transplant Surgery, Medical University of Gdańsk
Beta cell replacement therapy
ABSTRACT
Beta cell replacement therapy is currently the only 
treatment method that allows restoration of physio-
logical endogenous insulin secretion in the amounts 
corresponding to the current body requirements. Beta 
cell replacement options available for highly selected 
patients with brittle type 1 diabetes include solid-
-organ pancreas and islet transplantation. Beta cell 
replacement therapy may be offered to patients with 
both good kidney function and renal failure. In pro-
gressive renal failure, beta cell transplantation may be 
performed simultaneously with kidney transplantation 
or afterwards. Islet autotransplantation is offered to 
patients submitted to total pancreatectomy. In patients 
with brittle type 1 diabetes who continue to experience 
life threatening severe hypoglycaemia episodes despite 
optimized insulin therapy, beta cell replacement helps 
improve hypoglycaemia awareness, thus reducing the 
risk of severe hypoglycaemia episodes, facilitates blood 
glucose control with normalization of haemoglobin 
A1c (HbA1c) level, and reduces microvascular disease 
progression. In patients undergoing total pancrea-
tectomy, infusion of the patient’s own islets isolated 
from the removed pancreas prevents blood glucose 
level excursions and reduces the risk of surgically-
-induced diabetes. In this article, we review the current 
indications and contraindications to beta cell replace-
ment, expected benefits, and possible complications 
of beta cell transplantation. (Clin Diabetol 2020; 
9; 5: 344–355)
Key words: solid-organ pancreas transplantation, 
pancreatic islet transplantation, severe 
hypoglycaemia, diabetes type 1, total 
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Introduction
Due to the lack of other causal treatments for dia-
betes type 1, both pancreas transplantation and islet 
transplantation remain the only methods to restore 
physiological secretion of endogenous insulin. All other 
therapeutic options offered to patients with diabetes 
type 1 are limited to attempts to achieve near nor-
moglycaemia using insulin preparations administered 
subcutaneously.
Beta cell transplantation is a complex therapeutic 
process including patient selection, i.e., determining 
indications for and contraindications to the procedure; 
immunological assessment; evaluation of the technical 
feasibility of the procedure; donor selection along with 
procurement, storage, and appropriate preparation of 
the organ for transplantation; performing the trans-
plantation procedure; and immunosuppressive therapy 
and monitoring the function of the transplanted organ 
with constant evaluation of the patient health status. 
In the case of pancreatic islet transplantation, it is also 
necessary to perform pancreatic islet isolation to obtain 
islets that fulfil the qualitative and quantitative criteria 
to allow their administration to the patient.
The effectiveness of beta cell transplantation is 
usually limited in time, and the availability of this 
method for patients is limited by possible complications 
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of more or less invasive procedures and the need for 
immunosuppressive therapy. However, it is a valuable 
treatment option which may significantly improve 
patients’ quality of life, delay development of chronic 
complications, or even prolong life in carefully selected 
patients in whom the expected benefits and risks were 
appropriately weighted.
Available forms of beta cell  
transplantation
In clinical practice, the available forms of beta 
cell transplantation offered to patients with diabetes 
type 1 include transplantation of the whole pancreas 
procured from a deceased donor and transplantation 
of pancreatic islets isolated from a pancreas procured 
from a deceased donor. Both these procedures may be 
performed in three variants: 
1. pancreas transplantation alone (PTA)/islet trans-
plantation alone (ITA);
2. simultaneous pancreas and kidney (SPK) trans-
plantation/simultaneous islet and kidney trans-
plantation (SIKTx);
3. pancreas after kidney (PAK) transplantation/islets 
after kidney (IAK) transplantation.
The most commonly offered solution is a simul-
taneous transplantation of a pancreas and a kidney 
procured from the same deceased donor, performed 
in patients with diabetes type 1 who developed 
end-stage renal disease requiring chronic renal re-
placement therapy due to diabetic nephropathy. 
Simultaneous pancreas and kidney transplantation 
may also be pre-emptive i.e., in patients with end-
stage renal disease but before dialysis treatment is 
commenced. The second most common procedure 
is pancreas transplantation in a patient after earlier 
kidney transplantation from a deceased or living 
donor. Other treatment options are employed much 
less often. According to the data from the Interna-
tional Pancreas Transplant Registry (IPTR), a total of 
11,104 pancreas transplantation procedures were 
performed worldwide in 2005–2014, including 74% 
of simultaneous kidney and pancreas transplanta-
tions, 17% of pancreas after kidney transplanta-
tions and 9% of pancreas transplants alone [1]. 
According to the Poltransplant data, 20 kidney and 
pancreas transplantation or pancreas transplantation 
alone procedures were performed in Poland in 2018. 
The transplantation waiting list in our country in-
cludes approximately 50 patients (including 10 await-
ing pancreas transplantation alone) [2]. Attempts 
to transplant a pancreas fragment retrieved from 
a living donor have also been reported but this is not 
a routine procedure and it is not performed in Poland.
According to the Collaborative Islet Transplant 
Registry (CITR), a total of 2150 pancreatic islet trans-
plantations involving 2619 donors and 1086 recipients 
were performed worldwide in 1999–2015 [3].
Centres performing beta cell transplantation pro-
cedures in Poland are listed in Table 1.
Indications for pancreas  
and pancreatic islet transplantation
The rationale for simultaneous pancreas or pan-
creatic islet transplantation and kidney transplanta-
tion, and pancreas or pancreatic islet transplantation 
in patients with a functioning transplanted kidney is 
to improve long-term outcomes compared to kidney 
transplantation alone. The prognosis is improved by a 
positive effect of long-term normoglycaemia, prevent-
ing the development of chronic micro- and macroan-
giopathic complications [4–10].
Indications for beta cell transplantation, either as 
the solid-organ pancreas or isolated pancreatic islets, 
in the remaining cases, i.e., in patients with diabetes 
type 1 and functioning native kidneys, have been 
summarized in the 2018 International Pancreas and 
Islets Transplant Association/European Pancreas and 
Islets Transplant Association (IPITA/EPITA) guidelines. 
Indications for beta cell transplantation include at 
least one documented severe hypoglycaemia episode 
during the preceding year, the proportion of time with 
low blood glucose levels (< 54 mg/dL) ≥ 5% during 
continuous glucose monitoring (CGM) or hypogly-
caemia unawareness along with indicators of poor 
metabolic control (haemoglobin A1c [HbA1c] level > 
7.5–8.0%) or excessive blood glucose excursions, such 
as the CGM coefficient of variation ≥ 30% or standard 
deviation of blood glucose levels during CGM ≥ 40 mg/ 
/dL [11]. Another indication for pancreas or pancreatic 
islet transplantation alone in patients with good renal 
function are recurrent episodes of ketoacidosis despite 
individually optimized insulin treatment. Beta cell trans-
plantation is associated with the need for immuno-
suppressive treatment for the duration of functioning 
of the transplanted pancreas/pancreatic islets. Thus, 
simultaneous beta cell and kidney transplantation or 
beta cell transplantation alone as either the solid-organ 
pancreas or isolated pancreatic islets in patients after 
earlier transplantation of a kidney or another vascular-
ized organ (lung, heart) seems the optimal approach 
as beta cell transplantation in such cases is performed 
in patients receiving immunosuppressive therapy to 
prevent rejection of the other transplanted organ. In 
these patients, indications for beta cell transplantation 
are somewhat less rigorous compared to patients with 
diabetes type 1 and a good function of native kidneys.
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Contraindications to pancreas and 
pancreatic islet transplantation
When selecting patients for pancreas or pancre-
atic islet transplantation, it is necessary to consider 
contraindications to both the procedure itself and 
long-term immunosuppressive treatment. Absolute 
contraindications are the same and include a malig-
nancy (with a waiting period post successful treatment), 
persistent untreated infection, severe irreversible sys-
temic disease with limited life expectancy, and lack of 
patient compliance, e.g., due to alcohol abuse, drug 
addiction, or a mental disorder. A large body mass is 
also a contraindication to beta cell transplantation. In 
case of pancreas transplantation, obesity is associated 
with an increased risk of postoperative complications 
including thrombosis, infection, and pancreatic graft 
inflammation. In the case of pancreatic islet trans-
plantation, large body mass is usually associated with 
high insulin resistance which significantly limits the 
effectiveness of the procedure.
Table 1. Pancreas and pancreatic islet transplantation centres in Poland
Pancreatic islet transplantation — GDAŃSK
Klinika Chirurgii Ogólnej, Endokrynologicznej i Transplantacyjnej
Uniwersyteckie Centrum Kliniczne w Gdańsku, Centrum Medycyny Inwazyjnej
ul. Smoluchowskiego 17, 80–210 Gdańsk
phone: 58 349 30 10
fax: 58 349 30 50
e-mail: ichir@gumed.edu.pl
Solid-organ pancreas transplantation — KATOWICE, SZCZECIN, WARSZAWA
Oddział Chirurgii Ogólnej, Naczyniowej i Transplantacyjnej
SPSK im. A. Mielęckiego, Śląski Uniwersytet Medyczny w Katowicach
ul. Francuska 20–24, 40–027 Katowice 
phone: 32 259 15 20, 32 255 50 52 
fax: 32 255 50 52
e-mail: chirurgia_ogolna@spskm.katowice.pl
Klinika Chirurgii Ogólnej i Transplantacyjnej PUM 
al. Powstańców Wlkp. 72, 70–111 Szczecin
phone: 91 466 11 29
fax: 91 466 11 30
e-mail: chirurgia.transplantacyjna@spsk2-szczecin.pl
Katedra i Klinika Chirurgii Ogólnej, Naczyniowej i Transplantacyjnej WUM
Samodzielny Publiczny Centralny Szpital Kliniczny
ul. Banacha 1a, 02–097 Warszawa
phone: 22 599 24 67, 22 599 24 68, 22 599 10 98
fax: 22 59914 68
e-mail: knt.csk@uckwum.pl
Klinika Chirurgii Gastroenterologicznej i Transplantologii  
Centralny Szpital Kliniczny MSW
ul. Wołoska 137, 02–507 Warszawa 
phone: 22 508 12 17
fax: 22 508 12 66 
e-mail: transplantologia@cskmswia.pl
Katedra i Klinika Chirurgii Ogólnej i Transplantacyjnej
Instytut Transplantologii WUM
Szpital Kliniczny Dzieciątka Jezus
ul. Nowogrodzka 59, 02–006 Warszawa
phone: 22 502 17 83, 22 502 17 84
fax: 22 502 21 55
e-mail: chirurgia.ogolna.skdj@uckwum.pl
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Other contraindications to pancreas transplanta-
tion include advanced atherosclerotic iliac artery disease 
which precludes the procedure and general contrain-
dications to a major surgery, such as severe coronary 
artery disease or heart failure.
Contraindications to pancreatic islet transplanta-
tion, in addition to insulin resistance with the mean 
daily insulin requirement of > 1 unit/kg body mass, 
include cirrhosis, active liver disease with the evidence 
of liver damage, portal hypertension, and renal failure. 
In patients with progressive chronic kidney disease with 
the estimated glomerular filtration rate (GFR) between 
30 and 50 mL/min/1.73 m2, simultaneous kidney and 
pancreatic islet transplantation should be considered, 
or beta cell transplantation should be postponed until 
after kidney transplantation.
Detailed indications for and contraindications to 
pancreatic islet transplantation in various clinical sce-
narios are shown in Tables 2, 3 and in Figure 1 A, B.
Pancreas transplantation procedure
Pancreas transplantation is a major surgery per-
formed under general anaesthesia which requires, 
in addition to vascular anastomoses, anastomosing 
the duodenum of the donor with the intestine or the 
urinary bladder of the recipient for pancreatic juice 
drainage. The pancreas is transplanted heterotopi-
cally. Before transplantation, the vascular supply of 
Table 2. Indications for and contraindications to pancreatic islet transplantation in patients with diabetes type 1 and 
normal native kidney function
Indications
Diabetes type 1 with at least one of the following complications:
• At least one documented episode of severe hypoglycaemia (requiring the help of other persons) during the preceding year
• Proportion of low blood glucose levels (< 54 mg/dL) during CGM ≥ 5%
• Hypoglycaemia unawareness with Gold score ≥ 5
• Metabolic lability defined as at least 2 hospitalizations per year due to ketoacidosis
Along with indicators of poor metabolic control:
• HbA1c level > 7.5–8.0% 
• CGM coefficient of variation ≥ 30% or
• Standard deviation of blood glucose levels during CGM ≥ 40 mg/dL
Contraindications
Absolute contraindications:
• Unstable or untreated proliferative diabetic retinopathy
• Active infection, including viral hepatitis B or C
• Invasive aspergillosis, histoplasmosis, or coccidioidomycosis within last 12 months
• Severe concomitant cardiovascular disease: myocardial infarction within last 6 months, heart failure with left ventricular ejection 
fraction < 30%
• Creatinine clearance < 50 mL/min based on 24-hour urine collection and/or eGFR (CKD-EPI equation) < 50 mL/min/1.73 m2 (If 
evaluation of renal function using these methods is suspected to be inadequate, more precise evaluation may be indicated, e.g., 




• Active malignancy or cured malignancy before the end of appropriate waiting period
• Positive pregnancy test
• Positive cross-match test
• Alcohol or drug abuse
• Unstable mental disorder or mental disorder not controlled by medications, lack of compliance due to mental status changes re-
lated to diabetes
• Inability to provide informed consent
Relative contraindications:
• Smoking (6-month abstinence is required)
• Active peptic ulcer disease
• A history of liver disease or abnormal liver function tests, i.e., aminotransferase (ALT/AST) activity > 3 × upper limit of normal  
values, except for Gilbert syndrome
ALT — alanine transaminase; AST — aspartate transaminase; CGM — continuous glucose monitoring; CKD-EPI — Chronic Kidney Disease Epidemiology Col-
laboration; DTPA — diethylenetriamine pentaacetic acid; eGFR — estimated glomerular filtration rate; HbA1c — haemoglobin A1c
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the pancreas is reconstructed by anastomosing the 
superior mesenteric artery and the splenic artery of 
the procured pancreas with an Y-graft from the iliac 
artery of the recipient. Venous outflow is provided 
by the portal vein of the harvested pancreas which is 
anastomosed with the inferior vena cava or the iliac 
vein of the recipient. A much less commonly employed 
option is an anastomosis with the portal circulation 
of the recipient. The common iliac artery of the donor 
is anastomosed end-to-side with the external iliac 
artery of the recipient, and the pancreatic juice is 
drained by anastomosing the duodenum of the do-
nor mostly with the small intestine of the recipient. 
A duodeno-duodenal anastomosis is rarely performed. 
A duodenal-bladder anastomosis has become obsolete 
due to high complication rates.
Possible complications after pancreas 
transplantation
Pancreas transplantation is a technically challeng-
ing procedure with relatively high complication rates, 
leading to a loss of the transplanted organ in about 
Table 3. Indications for and contraindications to pancreatic islet transplantation in patients with diabetes type 1 after 
kidney or other vascularized organ transplantation
Indications
Diabetes type 1 with at least one of the following complications:
• At least one documented episode of severe hypoglycaemia (requiring the help of other persons) during the preceding year
• Proportion of low blood glucose levels (< 54 mg/dL) during CGM ≥ 5%
• Hypoglycaemia unawareness with Gold score ≥ 5
• Metabolic lability defined as at least 2 hospitalizations per year due to ketoacidosis
OR with indicators of poor metabolic control:
• HbA1c level > 7.5–8.0% 
• CGM coefficient of variation ≥ 30% or
• Standard deviation of blood glucose levels during CGM ≥ 40 mg/dL
Contraindications
Absolute contraindications:
• Unstable or untreated proliferative diabetic retinopathy
• Active infection, including viral hepatitis B or C
• Invasive aspergillosis, histoplasmosis, or coccidioidomycosis within last 12 months





• Active malignancy or cured malignancy before the end of appropriate waiting period
• Positive pregnancy test
• Positive cross-match test
• Alcohol or drug abuse
• Unstable mental disorder or mental disorder not controlled by medications, lack of compliance due to mental status changes re-
lated to diabetes
• Inability to provide informed consent
Relative contraindications:
• Smoking (6-month abstinence is required)
• Active peptic ulcer disease
• A history of liver disease or abnormal liver function tests, i.e., aminotransferase (ALT/AST) activity > 3 × upper limit of normal val-
ues, except for Gilbert syndrome
Specific contraindications in vascularized organ recipients:
• Advanced failure of the transplanted organ, including patients awaiting retransplantation
• Polyoma BK virus infection in kidney graft recipients
• Current complications of immunosuppressive therapy precluding its transient intensification
ALT — alanine transaminase; AST — aspartate transaminase; CGM — continuous glucose monitoring; HbA1c — haemoglobin A1c
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Figure 1. Indications for pancreas/pancreatic islet transplantation in selected clinical settings according to Wojtusciszyn et al. 
[17]. BMI — body mass index; eGFR — estimated glomerular filtration rate; HbA1c — haemoglobin A1c
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10% of cases. Another 15–20% of patients require reop-
eration due to bleeding, abscess or other complications. 
Mortality during the initial year after the procedure 
is several percent. The postoperative course is largely 
dependent on the appropriate donor and recipient 
selection. Pancreas graft vessel thrombosis (accounting 
for about 10–20% of the postoperative complications) 
manifests within the first week in 70% of patients 
and usually necessitates removal of the transplanted 
pancreas. It is the most common early cause of graft 
loss. Venous thrombosis is nearly twice more common 
than arterial thrombosis. Intraabdominal infection is the 
second most common complication. The most common 
pathogens are staphylococci, and the most common 
fungal pathogen is Candida albicans. Intraabdominal 
fungal infections are particularly dangerous and as-
sociated with an increased postoperative mortality. 
Mild, self-limiting graft pancreatitis is nearly universal 
due to transplant-related ischaemic injury. It may last 
for 3–4 weeks after the surgery. It manifests with pain 
in the graft area, fever, nausea, vomiting, and elevated 
inflammatory markers, while elevated amylase and lipase 
activity is not a universal finding. Inflammation may 
lead to necrosis and the development of peripancreatic 
abscesses, fistulae, or pancreatic pseudocysts. Intestinal 
fistula usually develops with 3 months after the trans-
plantation. It manifests as an acute abdomen and most 
patients require urgent surgery. Other possible complica-
tions include intraperitoneal or gastrointestinal bleeding 
from the pancreas or a leaking vascular anastomosis.
Pancreatic islet transplantation
Pancreatic islet transplantation involves infusion 
of pancreatic islets suspended in a solution contain-
ing human albumin and heparin to the portal vein of 
the patient. The portal vein is cannulated percutane-
ously and transhepatically under ultrasonographic 
and fluoroscopic guidance with local anaesthesia, or 
via colic vein branches by minilaparotomy under gen-
eral anaesthesia. During the infusion, pancreatic islets 
migrate to the liver where they engraft in the hepatic 
tissue and exert their endocrine function. To minimize 
the risk of portal vein thrombosis, pancreatic islets are 
separated from the exocrine tissue so that the total 
pellet volume does not exceed 12 mL.
In addition, pressure in the portal system is moni-
tored during the procedure. A portal vein pressure 
increase above 20 mm Hg or a twofold increase com-
pared to the baseline values necessitates temporary 
interruption of the infusion until the pressure norma-
lizes. In patients without liver disease, such pressure the 
increase is virtually never observed during the infusion 
of allogenic islets, even during the third or fourth trans-
plantation procedure. The risk is much higher during 
the infusion of autologous islets, particularly if the islet 
tissue volume exceeds 20 mL.
Until now, intrahepatic islet transplantation is 
the most optimal implantation site. Intrahepatic islet 
transplantation is associated with the preservation of 
insulin secretion to the liver which allows for the first 
pass effect and thus prevents hyperinsulinemia. At the 
same time, the pulsating nature of insulin secretion is 
preserved which has a beneficial effect on inhibiting 
hepatic glucose synthesis [12]. It is also possible to 
administer pancreatic islets to the intestine, spleen, 
renal capsule, and the peritoneal cavity but these ap-
proaches are rarely used due to their limited efficacy 
[13]. Although most effective, intrahepatic islet admini-
stration also has some downsides. Immediately after 
islet infusion to the portal vein bloodstream, an inflam-
matory process is triggered with platelet and leukocyte 
activation, leading to damage to significant proportion 
of islets, up to 50% [14]. Directly after the infusion, an 
elevation of transaminase activity to about 200 IU/mL 
is observed, with normalization within 2 weeks. During 
this time, the patients are prophylactically administered 
low-molecular-weight heparin subcutaneously.
Possible complications after pancreatic 
islet transplantation
Complications in the early period following pan-
creatic islet transplantation are rare, occurring in up 
to 10% of patients. The most common complications 
are bleeding from or into the liver (4%) and portal 
vein branch thrombosis (3%). Portal vein thrombosis 
occurs rarely, usually segmentally in small portal sys-
tem branches, has no clinical significance and typically 
resolves with anticoagulation without clinical sequelae, 
although it may theoretically lead to severe complica-
tions, with hepatic failure requiring liver transplantation 
or leading to death. In the later period, complications 
are mostly related to the immunosuppressive treat-
ment. Possible complications are listed in Table 4.
Pancreatic islet transplantation  
vs. pancreas transplantation
Pancreas transplantation is a major surgery per-
formed under general anaesthesia. About 10% of 
the recipients lose the graft shortly after the surgery, 
most commonly due to graft portal vein thrombosis. 
If the procedure is successful, patients do not require 
insulin immediately after the surgery, and 50–60% of 
patients continue to have preserved graft function 
and do not require exogenous insulin at 5 years after 
the transplantation. However, due to the extent of the 
surgery and the risk of postoperative complications, 
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Table 4. Possible complications associated with pancreatic islet transplantation
1. Risk of pancreatic islet cell infection 
As pancreatic islet cells undergo complex processing, there is a risk of bacterial infection during their isolation. There is also  
a risk of infection with donor’s bacteria. The risk of both is negligible as pancreatic islet isolation is performed in accordance  
to very restrictive procedures
2. Sensitivity to HLA antigens 
In such case, the organ availability for transplantation (e.g., kidney) will be more limited
3. Bleeding 
In very rare cases, a surgery is necessary to stop bleeding (1%) 
4. Portal vein thrombosis (3%) 
A complication of the procedure may be portal vein thrombosis resulting in partial or complete blood flow obstruction. This  
may frequently lead to transient laboratory test abnormalities (elevated transaminases) or very rarely to serious complications  
of liver failure. The risk of thrombosis is proportional to the amount of infused pancreatic islets. For this reason, only a very  
small volume (about 10 mL) is administered with heparin during the transplantation, and the procedure is followed by  
low-molecular-weight heparin prophylaxis for 14 days
5. Abdominal organ damage 
This may include a puncture of the gall bladder, large intestine, hepatic artery or other structures when infusing pancreatic islets 
Treatment of complications related to catheter placement in the portal vein may require surgery but the risk of such  
complications is small (< 5%)
6. Failure to achieve access to the portal vein 
For various reasons (e.g., previous thrombosis), the interventional radiologist may be unable to achieve access to the portal  
system. In such a situation, surgical islet transplantation is possible
7. Low blood pressure 
A rare complication is hypotension unrelated to bleeding, secondary to islet transplantation itself
8. Hypoglycaemia 
Severe hypoglycaemia may develop following islet transplantion due to insulin release from damaged islets
9. Failure to achieve non-insulin dependence 
Even if pancreatic islet transplantation is successful, the patient may still require insulin. In such a situation, options include 
another islet transplantation, solid-organ pancreas transplantation, or continuation of insulin therapy with appropriate dosing 
adjustment
10. Undetermined duration of transplanted islet function 
Even if baseline function of the transplanted islets is good, the duration of their functioning is unpredictable
11. Worsening of retinopathy 
The worsening of retinopathy may occur during the first year after pancreatic islet transplantation. These changes usually  
become stabilized beyond the first year
HLA — human leukocyte antigen
pancreas transplantation may only be performed in 
a small group of patients. In these patients, simul-
taneous kidney and pancreas transplantation is as-
sociated with a survival benefit compared to kidney 
transplantation alone, with the 10-year survival of 
67% in simultaneous kidney and pancreas transplant 
recipients compared to 56% and 36% in kidney 
transplant recipients from a living or deceased donor, 
respectively [1, 15]. All-cause mortality in simultane-
ous kidney and pancreas transplant recipients was 
20–30% lower compared to a deceased donor kidney 
transplant recipients during 10- and 20-year follow-
up, and 20% lower compared a living donor kidney 
transplant recipients during 20-year follow-up [16]. 
Pancreatic islet transplantation is a minimally invasive 
alternative to solid-organ pancreas transplantation 
and constitutes a safe surgical treatment method as-
sociated with no significant burden for the patient. 
This procedure is much easier and associated with 
a lower risk of complications but also with a much 
lower likelihood of achieving insulin independence. 
Transplantation outcomes depend mostly on the qual-
ity and quantity of infused islets per kg of body mass. 
Studies indicate that the desired amount that allows 
for a functional effect is at least 5000 islet equivalents 
(IEQ) per kilogram of body mass. Of an average of a mil-
lion of islets that are present in the pancreas, it is usu-
ally possible to retrieve about 300–500 thousand IEQ. 
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Table 5. Igls classification for the evaluation of transplanted pancreatic islet function
Islet function HbA1c (%) Severe hypoglycaemia episodes Insulin requirement (U/kg/d) Peptide C Success
Optimal ≤ 6.5 Absent No > baseline value Yes
Good < 7.0 Absent < 50% of baseline value*** > baseline value Yes
Marginal ≥ 7.0 < baseline freqency* ≥ 50% of baseline value > baseline value No*****
Failed As at baseline As at baseline** As at baseline As at  
baseline****
No
HbA1c — haemoglobin A1c
*If severe hypoglycaemia episodes were present before islet transplantation, determining benefits from transplantation requires assessment of the occur-
rence of severe hypoglycaemia episodes (< 3 mmol/L or 54 mg/dL), hypoglycaemia unawareness, and variation/lability of blood glucose levels
**If severe hypoglycaemia episodes were absent before islet transplantation, baseline indications for treatment are reevaluated
***Also glucose-lowering drugs other than insulin
****It is not a reliable indicator in patients with advanced renal failure and detectable peptide C level before islet transplantation
*****Clinically, benefits may still outweigh the risk associated with maintenance and monitoring of the residual function of transplanted islets
Of the isolated islets, ultimately less than half survive and 
produce insulin. The ultimate effect of transplantation 
may only be assessed several weeks after the procedure, 
as the islets require some time to engraft i.e. restore 
appropriate vascular supply. Only then they are able to 
provide normal synthesis of insulin, glucagon and other 
peptides in response to nutritional stimuli and blood 
glucose level. Of note, the patients ultimately receive 
less than half of the normal amount of islets in a healthy 
person during a single pancreatic islet transplantation. 
Thus, even if insulin independence is achieved, these 
patients have borderline beta cell function and only 
a small metabolic reserve. Reinitiation of insulin may be 
necessary with increased carbohydrate/caloric intake, 
reduced exercise, or weight gain. Reduced insulin sen-
sitivity is compensated by its increased secretion by 
beta cells. It seems that similarly to increased insulin 
resistance in diabetes type 2, compensatory hyperin-
sulinemia leads to exhaustion of the secretory function 
of the transplanted beta cells. Two or three sequential 
pancreatic islet transplantation procedures are usually 
necessary. According to the 2016 CITR data, insulin 
independence at 5 years was achieved in only 30% of 
patients after pancreatic islet transplantation alone and 
in 20% of patients after pancreatic islet transplantation 
following earlier kidney transplantation. Reports from 
single centres vary, with the proportion of patients 
showing insulin independence at 5 years ranging 
from 10% to as much as 60%. According to the most 
recent reports from France, although more than 60% 
of patients achieved insulin independence, the effect 
persisted at 5 years in less than 20% of patients [17, 18].
Achieving insulin independence, although possible, 
particularly with repeated islet infusions from several 
donors, is not the major goal of pancreatic islet trans-
plantation. The main goals are to stabilize the disease 
course, minimize the risk of chronic complications, 
and significantly reduce or even eliminate the risk of 
life-threatening severe hypoglycaemia. This has been 
reflected in the Igls classification designed to evaluate 
the function of transplanted pancreatic islets, devel-
oped in January 2017 based on the expert consensus 
during the 1st IPITA/EPITA Opinion Leaders Workshop 
in Igls, Austria (Table 5). Restoration of endogenous 
insulin secretion following pancreatic islet transplanta-
tion has a beneficial effect on lipid abnormalities, and 
preserved peptide C secretion, even in the absence of 
insulin independence, markedly limits the development 
of secondary diabetes complications, reducing the rate 
of life-threatening hypoglycaemia and protecting from 
the development of diabetic nephropathy, retinopathy, 
and enteropathy [19]. Even with only residual graft 
secretory function, patients do not experience severe 
symptomatic hypoglycaemia [20].
It seems that both approaches, i.e., solid-organ 
pancreas transplantation and isolated pancreatic islet 
transplantation may be considered complementary 
methods. In case of failed solid-organ pancreas trans-
plantation, pancreatic islet transplantation may be 
offered and vice versa. Both solid-organ pancreas trans-
plantation and pancreatic islet transplantation were 
shown to be beneficial in terms of reduced progression 
of macro- and microvascular complications compared 
to the conventional treatment [4–10].
The similarities of and differences between solid-
-organ pancreas transplantation and pancreatic islet 
transplantation are summarized in Table 6.
Total pancreas resection with pancreatic 
islet autotransplantation
It should be noted that pancreatic islet autotrans-
plantation is performed in patients undergoing total 
pancreatectomy due to intractable pain related to 
chronic pancreatitis. This procedure allows removal of 
the fibrosed pancreas and infusion of the isolated islets, 
even if not always providing insulin independence, 
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protects from excessive blood glucose level excursion 
and severe hypoglycaemia episodes. Selected centres 
worldwide have attempted pancreatic islet autotrans-
plantation in patients undergoing total pancreatectomy 
due to both benign and malignant tumours [21, 22].
Referral of a patient with brittle diabetes 
type 1 for pancreas or pancreatic islet 
transplantation
The approach to patient selection for pancreatic 
islet transplantation is shown in Figure 2. Patient selec-
tion for solid-organ pancreas transplantation is gener-
ally similar. A patient who fulfils the selection criteria 
and does not fulfil the disqualification criteria, based 
on the assessment of the general status, cardiovascular 
fitness, and technical feasibility of the procedure, after 
excluding infections and malignancies, is placed on the 
National Waiting List. The formal patient registration 
and selection occurs via the Transplantation Registry of 
the Ministry of Health (https://rejestrytx.gov.pl/tx/). The 
patient is registered by a physician from the pancreatic 
islet/pancreas transplantation centre. The recipient re-
ceives pancreatic islets from a donor with a compatible 
main blood group. Within the waiting list, priority is 
assigned to patients with the same main blood group 
and the lowest number of incompatible HLA antigens. 
Immediately before transplantation, cross-match test-
ing is performed using the serologic technique. Lym-
phocytes for cross-match testing are obtained from the 
lymph nodes of a deceased donor and exposed to the 
sera of potential recipients on the waiting list. Only the 
recipients with a negative cross-match test, i.e., without 
Table 6. Comparison of solid-organ pancreas transplantation and pancreatic islet transplantation
Pancreatic islet transplantation Solid-organ pancreas transplantation
Minimally invasive procedure involving percutaneous  
transhepatic puncture of a portal vein branch, usually  
under local anaesthesia
Major intrabdominal surgery requiring general anaesthesia
Complication rate about 10%, mostly bleedings  
and hematomas not requiring transfusion
Complication rate about 30%, including 1/3 leading to a loss of 
the transplanted organ. Complications often require reopera-
tion
Usually 2–3 sequential transplantations are needed Single procedure
Need for immunosuppressive therapy Need for immunosuppressive therapy
Reduces the risk of severe hypoglycaemia Reduces the risk of severe hypoglycaemia
Low likelihood of achieving durable non-insulin dependence High likelihood of achieving durable non-insulin dependence
Figure 2. Patient selection for pancreatic islet transplantation. ENT — ear, nose, and throat; HbA1c — haemoglobin A1c; HLA — 
human leukocyte antigen; PRA — panel reactive antibodies
Assessment of indications
Assessment of existing complications 
of diabetes
Assessment of procedure feasibility
Exclusion of potential infection foci
Screening for malignancies
Immunological assessment
• Severe hypoglycaemia episodes, hypoglycaemia unawareness




• Doppler ultrasound of the portal system
• Dental and ENT evaluation, Quantiferon-TB Gold
• Chest X-ray, abdominal ultrasound
• Chest X-ray, abdominal ultrasound, gastroscopy, colonoscopy
• Gynaecological and urological evaluation
• Anti-HLA antibodies, PRA
• Cross-match testing
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cytotoxic antibodies against donor HLA antigens, may 
be then considered for transplantation. Transplantation 
is then performed only if pancreatic islets of appropriate 
quantity and quality are isolated. Similarly to patients 
awaiting kidney transplantation from a deceased donor, 
the complement-dependent cytotoxicity test with panel 
reactive antibodies (PRA-CDC) and anti-HLA antibody 
solid phase assays are periodically performed to assess 
the degree of immunization.
Summary
Currently, both solid-organ pancreas transplan-
tation and pancreatic islet transplantation remain 
the only methods that allow restoration of physio-
logic endogenous insulin secretion. Pancreatic islet 
transplantation is a minimally invasive alternative to 
solid-organ pancreas transplantation and constitutes 
a safe surgical treatment method associated with 
no significant burden for the patient. It seems the 
optimal approach particularly in a kidney or another 
solid-organ transplant recipients who already receive 
immunosuppressive therapy to prevent rejection of the 
other transplanted organ.
Despite advances in the islet isolation technique 
and immunosuppressive therapy, a progressive loss of 
function of the transplanted islets is observed, and in 
most cases insulin independence is limited in time even 
in case of good baseline function of the transplanted 
beta cells. Thus, achieving insulin independence, is not 
the major goal of pancreatic islet transplantation. The 
main goals are to stabilize the disease course, minimize 
the risk of secondary complications, and eliminate the 
risk of life-threatening severe hypoglycaemia episodes. 
Solid-organ pancreas transplantation is associated 
with a higher risk of complications but offers a much 
higher likelihood of achieving insulin independence. 
Both these approaches to beta cell replacement seem 
a valuable therapeutic option in patients with brittle 
diabetes type 1, hypoglycaemia unawareness and recur-
rent severe hypoglycaemia episodes despite appropri-
ate education and optimized medical management.
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